NSPR vs. ELMD, INGN, NYXH, ZYXI, CATX, LUNG, RCEL, AVR, OBIO, and PROF
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include Electromed (ELMD), Inogen (INGN), Nyxoah (NYXH), Zynex (ZYXI), Perspective Therapeutics (CATX), Pulmonx (LUNG), AVITA Medical (RCEL), Anteris Technologies Global (AVR), Orchestra BioMed (OBIO), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.
InspireMD vs.
Electromed (NYSE:ELMD) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
Electromed has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Electromed has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Electromed has a net margin of 11.34% compared to InspireMD's net margin of -413.96%. Electromed's return on equity of 15.32% beat InspireMD's return on equity.
40.8% of Electromed shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 14.0% of Electromed shares are owned by insiders. Comparatively, 29.7% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Electromed received 10 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 87.50% of users gave Electromed an outperform vote while only 4.60% of users gave InspireMD an outperform vote.
InspireMD has a consensus price target of $4.75, indicating a potential upside of 80.61%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Electromed.
In the previous week, InspireMD had 1 more articles in the media than Electromed. MarketBeat recorded 3 mentions for InspireMD and 2 mentions for Electromed. InspireMD's average media sentiment score of 0.35 beat Electromed's score of 0.00 indicating that InspireMD is being referred to more favorably in the news media.
Summary
Electromed and InspireMD tied by winning 9 of the 18 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 2/5/2025 by MarketBeat.com Staff
